Use of β-Blockers in Pulmonary Hypertension - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Circulation. Heart failure Année : 2017

Use of β-Blockers in Pulmonary Hypertension

Résumé

Contrasting with the major attention that left heart failure has received, right heart failure remains understudied both at the preclinical and clinical levels. However, right ventricle failure is a major predictor of outcomes in patients with precapillary pulmonary hypertension because of pulmonary arterial hypertension, and in patients with postcapillary pulmonary hypertension because of left heart disease. In pulmonary hypertension, the status of the right ventricle is one of the most important predictors of both morbidity and mortality. Paradoxically, there are currently no approved therapies targeting the right ventricle in pulmonary hypertension. By analogy with the key role of β-blockers in the management of left heart failure, some authors have proposed to use these agents to support the right ventricle function in pulmonary hypertension. In this review, we summarize the current knowledge on the use of β-blockers in pulmonary hypertension.
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-01502296 , version 1 (05-04-2017)

Identifiants

Citer

Frédéric Perros, Frances S de Man, Harm J Bogaard, Fabrice Antigny, Gérald Simonneau, et al.. Use of β-Blockers in Pulmonary Hypertension. Circulation. Heart failure, 2017, 10 (4), pii: e00370. ⟨10.1161/CIRCHEARTFAILURE.116.003703⟩. ⟨inserm-01502296⟩
109 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More